Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.

NCT02107885

Safety Tolerability Pharmacokinetics

COMPLETED PHASE1

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323

Healthy Volunteers

COMPLETED PHASE1

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06453824

Safety and Tolerability

COMPLETED PHASE1

Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects

NCT01979380

Drug Toxicity

COMPLETED PHASE1

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546

Healthy Volunteers

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1, randomized, single-blind, placebo-controlled study of five escalating dose levels of SD-101 in healthy male volunteers. The objectives of the study are to assess the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of SD-101. Approximately 40 subjects will participate.

Once subjects have been consented, screened, and assigned to one of the dose levels of SD-101, subjects will receive a single subcutaneous injection of either SD-101 or placebo (PBS) in a ratio of 6:2.

Safety and tolerability will be evaluated by occurrence of adverse events, blood and urine laboratory tests, physical examination findings, vital signs , and electrocardiogram findings. Pharmacodynamics will be evaluated by levels of blood biomarkers and serum cytokines, and flow cytometric cell counts. Pharmacokinetics will be evaluated by levels of study drug in serum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escalating Dose of SD-101

Group Type EXPERIMENTAL

SD-101

Intervention Type DRUG

Single subcutaneous escalating dose

Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SD-101

Single subcutaneous escalating dose

Intervention Type DRUG

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed, written, informed consent must be obtained from the subjects before any study-specific procedures are performed.
* Subject must be male and 18 years of age or older.
* Subject must be willing to submit to a urine drug screen and agree to abstain from alcohol, caffeine, and tobacco during the required stay in the Phase I Unit.
* Subject must be willing to abide by the rules of the Phase 1 Unit.
* Subjects whose sexual partners are of childbearing potential must agree to use an effective method of birth control (i.e., chemical contraceptives, barrier plus spermicide, intrauterine device) during the treatment phase and for 14 days post treatment.
* Must be negative for Hepatitis B and C and human immunodeficiency virus (HIV).

Exclusion Criteria

* Females.
* Clinically significant active, acute, or chronic illness.
* History of coagulation or bleeding disorders.
* Clinically significant chronic or recent (within 21 days of dosing) acute gastrointestinal disorder with nausea, vomiting or diarrhea as a major symptom.
* Received any vaccine within 3 weeks of study entry or plans to be vaccinated within 6 weeks after study injection.
* History of significant cardiovascular or cerebrovascular disease.
* History of evaluation for autoimmune disease including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma or thyroiditis.
* Significant psychiatric illness that could potentially interfere with the assessments during this study.
* Subjects who have had prior surgery or a major infection within 6 months of dosing.
* History of medications within 7 days of dosing, except vitamins and/or minerals.
* History of Gilbert's disease.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes